vegf  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Boster Bio vegf
    Vegf, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf - by Bioz Stars, 2023-09
    86/100 stars

    Images

    vegf  (Boster Bio)


    Bioz Verified Symbol Boster Bio is a verified supplier
    Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Boster Bio vegf
    Vegf, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf - by Bioz Stars, 2023-09
    86/100 stars

    Images

    vegf  (Boster Bio)


    Bioz Verified Symbol Boster Bio is a verified supplier
    Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Boster Bio vegf
    Vegf, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf - by Bioz Stars, 2023-09
    86/100 stars

    Images

    rat vegf elisa kits  (Boster Bio)


    Bioz Verified Symbol Boster Bio is a verified supplier
    Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Boster Bio rat vegf elisa kits
    Rat Vegf Elisa Kits, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat vegf elisa kits/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat vegf elisa kits - by Bioz Stars, 2023-09
    86/100 stars

    Images

    human vegf elisa kit picokine tm  (Boster Bio)


    Bioz Verified Symbol Boster Bio is a verified supplier
    Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Boster Bio human vegf elisa kit picokine tm
    Human Vegf Elisa Kit Picokine Tm, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human vegf elisa kit picokine tm/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human vegf elisa kit picokine tm - by Bioz Stars, 2023-09
    86/100 stars

    Images

    vegf elisa kit  (Boster Bio)


    Bioz Verified Symbol Boster Bio is a verified supplier
    Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Boster Bio vegf elisa kit
    Vegf Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf elisa kit/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf elisa kit - by Bioz Stars, 2023-09
    86/100 stars

    Images

    vegf elisa kit  (Boster Bio)


    Bioz Verified Symbol Boster Bio is a verified supplier
    Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Boster Bio vegf elisa kit
    Vegf Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf elisa kit/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf elisa kit - by Bioz Stars, 2023-09
    86/100 stars

    Images

    human vegf elisa kit  (Boster Bio)


    Bioz Verified Symbol Boster Bio is a verified supplier
    Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Boster Bio human vegf elisa kit
    (A) Representative cytokines secreted by HREC, HRP and HRA after 48 h of EBO-VLP stimulation. Representative images of three independent experiments are shown. (B) Relative cytokine levels were normalized to the mock group without EBO-VLP administration, which was set as 1. The floating bar plot shows the mean, minimum and maximum levels of each cytokine in three independent experiments. Downregulation of cytokines expression were displayed with negative numbers. (C) Changes in <t>VEGF</t> expression after EBO-VLP administration, as quantified by <t>ELISA.</t> The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.
    Human Vegf Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human vegf elisa kit/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human vegf elisa kit - by Bioz Stars, 2023-09
    86/100 stars

    Images

    1) Product Images from "Ebola virus disrupts the inner blood-retinal barrier by induction of vascular endothelial growth factor in pericytes"

    Article Title: Ebola virus disrupts the inner blood-retinal barrier by induction of vascular endothelial growth factor in pericytes

    Journal: PLOS Pathogens

    doi: 10.1371/journal.ppat.1011077

    (A) Representative cytokines secreted by HREC, HRP and HRA after 48 h of EBO-VLP stimulation. Representative images of three independent experiments are shown. (B) Relative cytokine levels were normalized to the mock group without EBO-VLP administration, which was set as 1. The floating bar plot shows the mean, minimum and maximum levels of each cytokine in three independent experiments. Downregulation of cytokines expression were displayed with negative numbers. (C) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.
    Figure Legend Snippet: (A) Representative cytokines secreted by HREC, HRP and HRA after 48 h of EBO-VLP stimulation. Representative images of three independent experiments are shown. (B) Relative cytokine levels were normalized to the mock group without EBO-VLP administration, which was set as 1. The floating bar plot shows the mean, minimum and maximum levels of each cytokine in three independent experiments. Downregulation of cytokines expression were displayed with negative numbers. (C) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay, Standard Deviation

    (A-B) Integrity of the tri-culture iBRB model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (A) and the TEER values (B) of the iBRB model were examined 48 h after EBO-VLP administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (C) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRP. (D-E) Integrity of the iBRB co-culture (HRECs and HRPs) model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (D) and the TEER values (E) of the iBRB model were examined after 48 h of treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (F) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRA. (G-H) Integrity of the iBRB co-culture (HRECs and HRAs) model after EBO-VLP, EBO-VLP + Avastin, and VEGF treatment. Na-F permeability (G) and the TEER values (H) of the iBRB model were examined 48 h after EBO-VLP administration. All values were determined in ten independent experiments. (I) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. Pericytes were transfected with si-VEGF or nontargeting control siRNA, followed by treatment with EBO-VLP for 48 h. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (J-K) Integrity of the tri-culture iBRB model after EBO-VLP, si-VEGF + EBO-VLP, nontargeting control siRNA + EBO-VLP, and nontargeting control siRNA treatment. Na-F permeability (J) and the TEER values (K) of the iBRB model were examined 48 h after administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. All values were determined in six independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
    Figure Legend Snippet: (A-B) Integrity of the tri-culture iBRB model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (A) and the TEER values (B) of the iBRB model were examined 48 h after EBO-VLP administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (C) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRP. (D-E) Integrity of the iBRB co-culture (HRECs and HRPs) model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (D) and the TEER values (E) of the iBRB model were examined after 48 h of treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (F) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRA. (G-H) Integrity of the iBRB co-culture (HRECs and HRAs) model after EBO-VLP, EBO-VLP + Avastin, and VEGF treatment. Na-F permeability (G) and the TEER values (H) of the iBRB model were examined 48 h after EBO-VLP administration. All values were determined in ten independent experiments. (I) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. Pericytes were transfected with si-VEGF or nontargeting control siRNA, followed by treatment with EBO-VLP for 48 h. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (J-K) Integrity of the tri-culture iBRB model after EBO-VLP, si-VEGF + EBO-VLP, nontargeting control siRNA + EBO-VLP, and nontargeting control siRNA treatment. Na-F permeability (J) and the TEER values (K) of the iBRB model were examined 48 h after administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. All values were determined in six independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.

    Techniques Used: Permeability, Whisker Assay, Standard Deviation, Co-Culture Assay, Expressing, Enzyme-linked Immunosorbent Assay, Transfection

    (A) Western blot analysis of VLP-ΔGP using an anti-GP antibody. Representative images of three independent experiments are shown. (B) TEM image of VLP-ΔGP. (C) Permeability and (D) TEER of the tri-culture iBRB model were measured 48 h after VLP-ΔGP, VLP-ΔGP + Avastin and VEGF treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in six independent experiments. (E) The expression of VEGF in HRP after VLP-ΔGP treatment, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (F) The expression of VEGF in HRP after EBOV VP40 and GP was expressed in HRPs. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.
    Figure Legend Snippet: (A) Western blot analysis of VLP-ΔGP using an anti-GP antibody. Representative images of three independent experiments are shown. (B) TEM image of VLP-ΔGP. (C) Permeability and (D) TEER of the tri-culture iBRB model were measured 48 h after VLP-ΔGP, VLP-ΔGP + Avastin and VEGF treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in six independent experiments. (E) The expression of VEGF in HRP after VLP-ΔGP treatment, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (F) The expression of VEGF in HRP after EBOV VP40 and GP was expressed in HRPs. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.

    Techniques Used: Western Blot, Permeability, Whisker Assay, Standard Deviation, Expressing, Enzyme-linked Immunosorbent Assay

    human vegf elisa kit  (Boster Bio)


    Bioz Verified Symbol Boster Bio is a verified supplier
    Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Boster Bio human vegf elisa kit
    (A) Representative cytokines secreted by HREC, HRP and HRA after 48 h of EBO-VLP stimulation. Representative images of three independent experiments are shown. (B) Relative cytokine levels were normalized to the mock group without EBO-VLP administration, which was set as 1. The floating bar plot shows the mean, minimum and maximum levels of each cytokine in three independent experiments. Downregulation of cytokines expression were displayed with negative numbers. (C) Changes in <t>VEGF</t> expression after EBO-VLP administration, as quantified by <t>ELISA.</t> The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.
    Human Vegf Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human vegf elisa kit/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human vegf elisa kit - by Bioz Stars, 2023-09
    86/100 stars

    Images

    1) Product Images from "Ebola virus disrupts the inner blood-retinal barrier by induction of vascular endothelial growth factor in pericytes"

    Article Title: Ebola virus disrupts the inner blood-retinal barrier by induction of vascular endothelial growth factor in pericytes

    Journal: PLOS Pathogens

    doi: 10.1371/journal.ppat.1011077

    (A) Representative cytokines secreted by HREC, HRP and HRA after 48 h of EBO-VLP stimulation. Representative images of three independent experiments are shown. (B) Relative cytokine levels were normalized to the mock group without EBO-VLP administration, which was set as 1. The floating bar plot shows the mean, minimum and maximum levels of each cytokine in three independent experiments. Downregulation of cytokines expression were displayed with negative numbers. (C) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.
    Figure Legend Snippet: (A) Representative cytokines secreted by HREC, HRP and HRA after 48 h of EBO-VLP stimulation. Representative images of three independent experiments are shown. (B) Relative cytokine levels were normalized to the mock group without EBO-VLP administration, which was set as 1. The floating bar plot shows the mean, minimum and maximum levels of each cytokine in three independent experiments. Downregulation of cytokines expression were displayed with negative numbers. (C) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay, Standard Deviation

    (A-B) Integrity of the tri-culture iBRB model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (A) and the TEER values (B) of the iBRB model were examined 48 h after EBO-VLP administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (C) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRP. (D-E) Integrity of the iBRB co-culture (HRECs and HRPs) model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (D) and the TEER values (E) of the iBRB model were examined after 48 h of treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (F) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRA. (G-H) Integrity of the iBRB co-culture (HRECs and HRAs) model after EBO-VLP, EBO-VLP + Avastin, and VEGF treatment. Na-F permeability (G) and the TEER values (H) of the iBRB model were examined 48 h after EBO-VLP administration. All values were determined in ten independent experiments. (I) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. Pericytes were transfected with si-VEGF or nontargeting control siRNA, followed by treatment with EBO-VLP for 48 h. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (J-K) Integrity of the tri-culture iBRB model after EBO-VLP, si-VEGF + EBO-VLP, nontargeting control siRNA + EBO-VLP, and nontargeting control siRNA treatment. Na-F permeability (J) and the TEER values (K) of the iBRB model were examined 48 h after administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. All values were determined in six independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
    Figure Legend Snippet: (A-B) Integrity of the tri-culture iBRB model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (A) and the TEER values (B) of the iBRB model were examined 48 h after EBO-VLP administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (C) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRP. (D-E) Integrity of the iBRB co-culture (HRECs and HRPs) model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (D) and the TEER values (E) of the iBRB model were examined after 48 h of treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (F) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRA. (G-H) Integrity of the iBRB co-culture (HRECs and HRAs) model after EBO-VLP, EBO-VLP + Avastin, and VEGF treatment. Na-F permeability (G) and the TEER values (H) of the iBRB model were examined 48 h after EBO-VLP administration. All values were determined in ten independent experiments. (I) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. Pericytes were transfected with si-VEGF or nontargeting control siRNA, followed by treatment with EBO-VLP for 48 h. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (J-K) Integrity of the tri-culture iBRB model after EBO-VLP, si-VEGF + EBO-VLP, nontargeting control siRNA + EBO-VLP, and nontargeting control siRNA treatment. Na-F permeability (J) and the TEER values (K) of the iBRB model were examined 48 h after administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. All values were determined in six independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.

    Techniques Used: Permeability, Whisker Assay, Standard Deviation, Co-Culture Assay, Expressing, Enzyme-linked Immunosorbent Assay, Transfection

    (A) Western blot analysis of VLP-ΔGP using an anti-GP antibody. Representative images of three independent experiments are shown. (B) TEM image of VLP-ΔGP. (C) Permeability and (D) TEER of the tri-culture iBRB model were measured 48 h after VLP-ΔGP, VLP-ΔGP + Avastin and VEGF treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in six independent experiments. (E) The expression of VEGF in HRP after VLP-ΔGP treatment, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (F) The expression of VEGF in HRP after EBOV VP40 and GP was expressed in HRPs. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.
    Figure Legend Snippet: (A) Western blot analysis of VLP-ΔGP using an anti-GP antibody. Representative images of three independent experiments are shown. (B) TEM image of VLP-ΔGP. (C) Permeability and (D) TEER of the tri-culture iBRB model were measured 48 h after VLP-ΔGP, VLP-ΔGP + Avastin and VEGF treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in six independent experiments. (E) The expression of VEGF in HRP after VLP-ΔGP treatment, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (F) The expression of VEGF in HRP after EBOV VP40 and GP was expressed in HRPs. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.

    Techniques Used: Western Blot, Permeability, Whisker Assay, Standard Deviation, Expressing, Enzyme-linked Immunosorbent Assay

    rat vegf elisa kit  (Boster Bio)


    Bioz Verified Symbol Boster Bio is a verified supplier
    Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Boster Bio rat vegf elisa kit
    Antitumor effects of different siVEGF-delivery systems in nude mice bearing breast cancer via intravenous administration. ( A ) Images of mice on day 14 post administration. ( B ) Changes of animal weight with time. ( C ) Changes of tumor volume with time, * P < 0.01 vs saline only for data on day 14. ( D ) Relative <t>VEGF</t> protein level in tumor tissues (data from <t>ELISA),</t> * P < 0.01 vs saline. n = 5.
    Rat Vegf Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat vegf elisa kit/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat vegf elisa kit - by Bioz Stars, 2023-09
    86/100 stars

    Images

    1) Product Images from "Combined Self-Assembled iRGD Polymersomes for Effective Targeted siRNA Anti-Tumor Therapy"

    Article Title: Combined Self-Assembled iRGD Polymersomes for Effective Targeted siRNA Anti-Tumor Therapy

    Journal: International Journal of Nanomedicine

    doi: 10.2147/IJN.S383862

    Antitumor effects of different siVEGF-delivery systems in nude mice bearing breast cancer via intravenous administration. ( A ) Images of mice on day 14 post administration. ( B ) Changes of animal weight with time. ( C ) Changes of tumor volume with time, * P < 0.01 vs saline only for data on day 14. ( D ) Relative VEGF protein level in tumor tissues (data from ELISA), * P < 0.01 vs saline. n = 5.
    Figure Legend Snippet: Antitumor effects of different siVEGF-delivery systems in nude mice bearing breast cancer via intravenous administration. ( A ) Images of mice on day 14 post administration. ( B ) Changes of animal weight with time. ( C ) Changes of tumor volume with time, * P < 0.01 vs saline only for data on day 14. ( D ) Relative VEGF protein level in tumor tissues (data from ELISA), * P < 0.01 vs saline. n = 5.

    Techniques Used: Enzyme-linked Immunosorbent Assay

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Boster Bio vegf
    Vegf, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    86
    Boster Bio rat vegf elisa kits
    Rat Vegf Elisa Kits, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat vegf elisa kits/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat vegf elisa kits - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    86
    Boster Bio human vegf elisa kit picokine tm
    Human Vegf Elisa Kit Picokine Tm, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human vegf elisa kit picokine tm/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human vegf elisa kit picokine tm - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    86
    Boster Bio vegf elisa kit
    Vegf Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf elisa kit/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf elisa kit - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    86
    Boster Bio human vegf elisa kit
    (A) Representative cytokines secreted by HREC, HRP and HRA after 48 h of EBO-VLP stimulation. Representative images of three independent experiments are shown. (B) Relative cytokine levels were normalized to the mock group without EBO-VLP administration, which was set as 1. The floating bar plot shows the mean, minimum and maximum levels of each cytokine in three independent experiments. Downregulation of cytokines expression were displayed with negative numbers. (C) Changes in <t>VEGF</t> expression after EBO-VLP administration, as quantified by <t>ELISA.</t> The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.
    Human Vegf Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human vegf elisa kit/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human vegf elisa kit - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    86
    Boster Bio rat vegf elisa kit
    Antitumor effects of different siVEGF-delivery systems in nude mice bearing breast cancer via intravenous administration. ( A ) Images of mice on day 14 post administration. ( B ) Changes of animal weight with time. ( C ) Changes of tumor volume with time, * P < 0.01 vs saline only for data on day 14. ( D ) Relative <t>VEGF</t> protein level in tumor tissues (data from <t>ELISA),</t> * P < 0.01 vs saline. n = 5.
    Rat Vegf Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat vegf elisa kit/product/Boster Bio
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat vegf elisa kit - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    Image Search Results


    (A) Representative cytokines secreted by HREC, HRP and HRA after 48 h of EBO-VLP stimulation. Representative images of three independent experiments are shown. (B) Relative cytokine levels were normalized to the mock group without EBO-VLP administration, which was set as 1. The floating bar plot shows the mean, minimum and maximum levels of each cytokine in three independent experiments. Downregulation of cytokines expression were displayed with negative numbers. (C) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.

    Journal: PLOS Pathogens

    Article Title: Ebola virus disrupts the inner blood-retinal barrier by induction of vascular endothelial growth factor in pericytes

    doi: 10.1371/journal.ppat.1011077

    Figure Lengend Snippet: (A) Representative cytokines secreted by HREC, HRP and HRA after 48 h of EBO-VLP stimulation. Representative images of three independent experiments are shown. (B) Relative cytokine levels were normalized to the mock group without EBO-VLP administration, which was set as 1. The floating bar plot shows the mean, minimum and maximum levels of each cytokine in three independent experiments. Downregulation of cytokines expression were displayed with negative numbers. (C) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.

    Article Snippet: The amount of VEGF in the supernatant was measured by a Human VEGF ELISA Kit (Boster, EK0539).

    Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Standard Deviation

    (A-B) Integrity of the tri-culture iBRB model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (A) and the TEER values (B) of the iBRB model were examined 48 h after EBO-VLP administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (C) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRP. (D-E) Integrity of the iBRB co-culture (HRECs and HRPs) model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (D) and the TEER values (E) of the iBRB model were examined after 48 h of treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (F) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRA. (G-H) Integrity of the iBRB co-culture (HRECs and HRAs) model after EBO-VLP, EBO-VLP + Avastin, and VEGF treatment. Na-F permeability (G) and the TEER values (H) of the iBRB model were examined 48 h after EBO-VLP administration. All values were determined in ten independent experiments. (I) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. Pericytes were transfected with si-VEGF or nontargeting control siRNA, followed by treatment with EBO-VLP for 48 h. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (J-K) Integrity of the tri-culture iBRB model after EBO-VLP, si-VEGF + EBO-VLP, nontargeting control siRNA + EBO-VLP, and nontargeting control siRNA treatment. Na-F permeability (J) and the TEER values (K) of the iBRB model were examined 48 h after administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. All values were determined in six independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.

    Journal: PLOS Pathogens

    Article Title: Ebola virus disrupts the inner blood-retinal barrier by induction of vascular endothelial growth factor in pericytes

    doi: 10.1371/journal.ppat.1011077

    Figure Lengend Snippet: (A-B) Integrity of the tri-culture iBRB model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (A) and the TEER values (B) of the iBRB model were examined 48 h after EBO-VLP administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (C) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRP. (D-E) Integrity of the iBRB co-culture (HRECs and HRPs) model after EBO-VLP, EBO-VLP + Avastin and VEGF treatment. Na-F permeability (D) and the TEER values (E) of the iBRB model were examined after 48 h of treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in ten independent experiments. (F) Experimental schematic showing the addition of EBO-VLPs to the iBRB co-culture model of HREC and HRA. (G-H) Integrity of the iBRB co-culture (HRECs and HRAs) model after EBO-VLP, EBO-VLP + Avastin, and VEGF treatment. Na-F permeability (G) and the TEER values (H) of the iBRB model were examined 48 h after EBO-VLP administration. All values were determined in ten independent experiments. (I) Changes in VEGF expression after EBO-VLP administration, as quantified by ELISA. Pericytes were transfected with si-VEGF or nontargeting control siRNA, followed by treatment with EBO-VLP for 48 h. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (J-K) Integrity of the tri-culture iBRB model after EBO-VLP, si-VEGF + EBO-VLP, nontargeting control siRNA + EBO-VLP, and nontargeting control siRNA treatment. Na-F permeability (J) and the TEER values (K) of the iBRB model were examined 48 h after administration. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. All values were determined in six independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.

    Article Snippet: The amount of VEGF in the supernatant was measured by a Human VEGF ELISA Kit (Boster, EK0539).

    Techniques: Permeability, Whisker Assay, Standard Deviation, Co-Culture Assay, Expressing, Enzyme-linked Immunosorbent Assay, Transfection

    (A) Western blot analysis of VLP-ΔGP using an anti-GP antibody. Representative images of three independent experiments are shown. (B) TEM image of VLP-ΔGP. (C) Permeability and (D) TEER of the tri-culture iBRB model were measured 48 h after VLP-ΔGP, VLP-ΔGP + Avastin and VEGF treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in six independent experiments. (E) The expression of VEGF in HRP after VLP-ΔGP treatment, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (F) The expression of VEGF in HRP after EBOV VP40 and GP was expressed in HRPs. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.

    Journal: PLOS Pathogens

    Article Title: Ebola virus disrupts the inner blood-retinal barrier by induction of vascular endothelial growth factor in pericytes

    doi: 10.1371/journal.ppat.1011077

    Figure Lengend Snippet: (A) Western blot analysis of VLP-ΔGP using an anti-GP antibody. Representative images of three independent experiments are shown. (B) TEM image of VLP-ΔGP. (C) Permeability and (D) TEER of the tri-culture iBRB model were measured 48 h after VLP-ΔGP, VLP-ΔGP + Avastin and VEGF treatment. TEER values were normalized to those of iBRB models themselves before EBO-VLP administration. The box and the whisker present the median ± percentiles (25–75%) and range, respectively. The fold change of permeability compared with iBRB model itself before EBO-VLP administration is presented as the mean ± standard deviation. All values were determined in six independent experiments. (E) The expression of VEGF in HRP after VLP-ΔGP treatment, as quantified by ELISA. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. (F) The expression of VEGF in HRP after EBOV VP40 and GP was expressed in HRPs. The horizontal dashed line marks the limit of detection of the assay. The results are presented as the means ± standard deviation of three independent experiments. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01.

    Article Snippet: The amount of VEGF in the supernatant was measured by a Human VEGF ELISA Kit (Boster, EK0539).

    Techniques: Western Blot, Permeability, Whisker Assay, Standard Deviation, Expressing, Enzyme-linked Immunosorbent Assay

    Antitumor effects of different siVEGF-delivery systems in nude mice bearing breast cancer via intravenous administration. ( A ) Images of mice on day 14 post administration. ( B ) Changes of animal weight with time. ( C ) Changes of tumor volume with time, * P < 0.01 vs saline only for data on day 14. ( D ) Relative VEGF protein level in tumor tissues (data from ELISA), * P < 0.01 vs saline. n = 5.

    Journal: International Journal of Nanomedicine

    Article Title: Combined Self-Assembled iRGD Polymersomes for Effective Targeted siRNA Anti-Tumor Therapy

    doi: 10.2147/IJN.S383862

    Figure Lengend Snippet: Antitumor effects of different siVEGF-delivery systems in nude mice bearing breast cancer via intravenous administration. ( A ) Images of mice on day 14 post administration. ( B ) Changes of animal weight with time. ( C ) Changes of tumor volume with time, * P < 0.01 vs saline only for data on day 14. ( D ) Relative VEGF protein level in tumor tissues (data from ELISA), * P < 0.01 vs saline. n = 5.

    Article Snippet: The concentration VEGF protein in supernatants was determined using a Rat VEGF ELISA Kit (Boster) according to the manufacturer’s instructions.

    Techniques: Enzyme-linked Immunosorbent Assay